A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel (CARTITUDE-10)
A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel
Sponsor: Janssen Research & Development, LLC
Listed as NCT07149857, this PHASE2 trial focuses on Multiple Myeloma and remains actively recruiting participants. Sponsored by Janssen Research & Development, LLC, it has been updated 6 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE2
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Research & Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Badalona, Spain , Barcelona, Spain , Camperdown, Australia , Heidelberg, Australia , Iowa City, United States , Madrid, Spain , Murdoch, Australia , New York, United States , Pamplona, Spain , Salamanca, Spain and 4 more locations